Compounded semaglutide, tirzepatide and liraglutide could be harder to come by starting this summer, if the U.S. Food and ...
A majority of GLP-1 lawsuits come from patients who allege that manufacturers have inadequately warned about severe side ...
FDA enforcement will focus on restricting GLP-1 APIs in mass-marketed, nonapproved compounded products to address unverifiable quality, safety, and efficacy under the FD&C Act. Appropriate compounding ...
There is no shortage of headlines about GLP-1 medications. Originally developed to manage blood sugar levels, these medications are now widely known for promoting weight loss. Alongside their rapid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results